Swedish Orphan Biovitrum AB(Sobi) has been pretty quiet on the business development front since an $8.1bn buyout by a private equity syndicate fell through at the end of last year but the company has now splashed out $55m upfront to get the rights in Europe and most international markets to ADC Therapeutics SA’s lymphoma treatment Zynlonta.
Sobi Returns To Deal-Making With ADC Lymphoma Licensing Pact
Pays $55m Upfront For Rights To Zynlonta
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
More from Rare Diseases
More from Scrip
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
• By
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.